An overview of the efficacy and safety of brexpiprazole for the treatment of schizophrenia in adolescents

Chesika J. CrumpMood Disorders Research Program, Depression Center, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USAView further author information

Hagar AbuelazmMood Disorders Research Program, Depression Center, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USAView further author information

Kirolos IbrahimMood Disorders Research Program, Depression Center, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USAView further author information

Shaishav ShahMood Disorders Research Program, Depression Center, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USAView further author information

Rif S. El-MallakhMood Disorders Research Program, Depression Center, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USACorrespondence[email protected]
View further author information

An overview of the efficacy and safety of brexpiprazole for the treatment of schizophrenia in adolescents

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

An overview of the efficacy and safety of brexpiprazole for the treatment of schizophrenia in adolescents

Figures & data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date